• Dr. Chatham's research program is focused on the biology of TNF family receptors and their ligands (including BLyS/BAFF) as these relate to disease expression in lupus and other inflammatory/autoimmune disorders. The therapeutic implication of these studies has been extended to current clinical studies that involve the use of monoclonal reagents and soluble receptors targeting BlyS/BAFF in patients with active systemic  lupus as well as their potential use in autoimmunity associated with immunodeficiency. Additional collaborative studies are examining the biology of type-1 interferons and  interferon-alpha blocking reagents on disease activity in systemic lupus and macrophage activation disorders
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Cutting edge: Intracellular IFN-β and distinct type i IFN expression patterns in circulating systemic lupus erythematosus B cellsJournal of Immunology.  201:2203-2208. 2018
    2018 Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort StudyArthritis Care and Research.  70:1478-1487. 2018
    2017 A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosusLupus.  26:1483-1490. 2017
    2017 Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled TrialsArthritis and Rheumatology.  69:362-375. 2017
    2016 Extensive Pyoderma Gangrenosum Associated with Granulomatosis with Polyangiitis with Both Responsive to RituximabJCR: Journal of Clinical Rheumatology.  22:392-394. 2016
    2016 A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosisJournal of Immunology.  196:2492-2503. 2016
    2016 Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial∗Critical Care Medicine.  44:275-281. 2016
    2016 Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genesClinical and Experimental Rheumatology.  34:953. 2016
    2015 Minorities with lupus nephritis and medications: A study of facilitators to medication decision-makingArthritis Research.  17. 2015
    2015 Barriers to medication decision making in women with lupus nephritis: A formative study using nominal group techniqueJournal of Rheumatology.  42:1616-1623. 2015
    2015 Does viral hemorrhagic fever represent reactive hemophagocytic syndrome?Journal of Rheumatology.  42:1078-1080. 2015
    2015 Randomized, double-blind, placebo-controlled trial of the effect of vitamin D<inf>3</inf> on the interferon signature in patients with systemic lupus erythematosusArthritis and Rheumatology.  67:1848-1857. 2015
    2015 Vasculitis related to viral and other microbial agentsBest Practice and Research: Clinical Rheumatology.  29:226-243. 2015
    2014 Cell-bound complement activation products in systemic lupus erythematosus: Comparison with anti-double-stranded DNA and standard complement measurementsLupus Science & Medicine.  1. 2014
    2014 Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusJournal of Rheumatology.  41:300-309. 2014
    2014 Macrophage Activation Syndrome Secondary to Human Monocytic EhrlichiosisIndian Journal of Hematology and Blood Transfusion.  30:145-147. 2014
    2013 Genome-Wide DNA Methylation Analysis of Systemic Lupus Erythematosus Reveals Persistent Hypomethylation of Interferon Genes and Compositional Changes to CD4+ T-cell PopulationsPLoS Genetics.  9. 2013
    2012 Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosusArthritis and Rheumatism.  64:4040-4047. 2012
    2012 Device for carrying blood samples at 37°C for cryoglobulin testClinical and Diagnostic Laboratory Immunology.  19:1555-1556. 2012
    2012 Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trialJournal of Rheumatology.  39:1632-1640. 2012
    2012 Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosusArthritis and Rheumatism.  64:2328-2337. 2012
    2012 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care and Research.  64:635-639. 2012
    2012 Systemic lupus erythematosus: Genomics, mechanisms, and therapiesClinical and Developmental Immunology.  2012. 2012
    2011 A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis and Rheumatism.  63:3918-3930. 2011
    2011 B lymphocytes are resistant to death receptor 5-induced apoptosisClinical Immunology.  139:21-31. 2011
    2010 Report of the American College of Rheumatology Pain Management Task ForceArthritis Care and Research.  62:590-599. 2010
    2010 Rheumatic manifestations of systemic disease: SarcoidosisCurrent Opinion in Rheumatology.  22:85-90. 2010
    2009 A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Care and Research.  61:1168-1178. 2009
    2009 Novel evidence-based systemic lupus erythematosus responder indexArthritis Care and Research.  61:1143-1151. 2009
    2009 Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritisScandinavian Journal of Immunology.  70:309-316. 2009
    2009 Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneityJournal of Clinical Investigation.  119:1668-1677. 2009
    2008 Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosusArthritis Research.  10. 2008
    2008 Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusArthritis and Rheumatism.  58:2453-2459. 2008
    2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisArthritis Care and Research.  59:762-784. 2008
    2006 Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol? CommentaryNature Clinical Practice Rheumatology.  2:240-241. 2006
    2006 Improving ambulatory prescribing safety with a handheld decision support system: A randomized controlled trialJournal of the American Medical Informatics Association.  13:171-179. 2006
    2006 Ultrasound appearance of knuckle pads.Skeletal Radiology.  35:823-827. 2006
    2005 Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosusArthritis and Rheumatism.  52:3943-3954. 2005
    2003 FcγRIIIb Allele-Sensitive Release of α-Defensins: Anti-Neutrophil Cytoplasmic Antibody-Induced Release of ChemotaxinsJournal of Immunology.  171:6090-6096. 2003
    2002 Normal radiographs in patients with persistent "hip pain" - Value of magnetic resonance imagingJournal of Rheumatology.  29:2463-2465. 2002
    2002 Immune function in patients with rheumatoid arthritis treated with etanerceptClinical Immunology.  103:13-21. 2002
    2001 Treatment of lupus with corticosteroidsLupus.  10:140-147. 2001
    2000 Renal failure: A risk factor for methotrexate toxicityArthritis and Rheumatism.  43:1185-1186. 2000
    1999 Update on sarcoidosisCurrent Opinion in Rheumatology.  11:83-87. 1999
    1998 Ligation of CR1 attenuates Fc receptor-mediated myeloperoxidase release and HOCl production by neutrophilsJournal of Leukocyte Biology.  63:477-485. 1998
    1996 Acidic fibroblast growth factor (FGF-1) enhances huvec expression of ICAM-1 induced by IL-1βFederation proceedings.  10. 1996
    1996 Characterization of PepB, a group B streptococcal oligopeptidaseInfection and Immunity.  64:3401-3406. 1996
    1995 Effects of tenidap on superoxide-generating enzymes. Non-competitive inhibition of xanthine oxidaseBiochemical Pharmacology.  50:811-814. 1995
    1995 Activation of human neutrophils by surface-associated IgA is associated with the release of activated collagenaseClinical immunology and immunopathology.  76:241-247. 1995
    1995 Progressive joint destruction in a human immunodeficiency virus‐infected patient with rheumatoid arthritisArthritis and Rheumatism.  38:1328-1332. 1995
    1995 Rheumatoid synovial fibroblast adhesion to human articular cartilageArthritis and Rheumatism.  38:1694-1700. 1995
    1994 Determinants of neutrophil HOCl generation: Ligand-dependent responses and the role of surface adhesionJournal of Leukocyte Biology.  56:654-660. 1994
    1994 HOCl production by human neutrophils activated by surface-associated IgG: Requirement for influx of extracellular calciumJournal of Leukocyte Biology.  55:793-797. 1994
    1993 Degradation of human articular cartilage by neutrophils in synovial fluidArthritis and Rheumatism.  36:51-58. 1993
    1993 Fixation of C3 to IgG attenuates neutrophil HOCl generation and collagenase activationJournal of Immunology.  151:949-958. 1993
    1992 Additive enhancement of neutrophil collagenase activity by HOCl and cathepsin GBiochemical and Biophysical Research Communications.  184:560-567. 1992
    1992 Ligand dependent release of activated neutrophil collagenase--a role for surface bound IgG in the degradation of articular collagens.Matrix (Stuttgart, Germany). Supplement.  1:207-208. 1992
    1991 Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenaseArthritis and Rheumatism.  34:211-216. 1991
    1990 Letter to the editor (I)Arthritis and Rheumatism.  3:104-105. 1990
    1990 Letter to the editor (I)Arthritis and Rheumatism.  3:104-105. 1990
    1990 LettersArthritis and Rheumatism.  3:104-105. 1990
    1990 Ligand‐dependent release of active neutrophil collagenaseArthritis and Rheumatism.  33:228-234. 1990
    1990 Lysis of fibrillar collagen by neutrophils in synovial fluid. A Role for Surface‐Bound ImmunoglobulinsArthritis and Rheumatism.  33:1333-1339. 1990
    1989 The replyAmerican Journal of Medicine.  86:634. 1989
    1989 Valvular Heart Disease in Systemic Lupus ErythematosusNew England Journal of Medicine.  320:739-741. 1989
    1989 Intraarticular corticosteroid injections: Should we rest the joints?Arthritis and Rheumatism.  2:70-74. 1989
    1989 Intraarticular corticosteroid injections: Should we rest the joints?Arthritis and Rheumatism.  2:70-74. 1989
    1988 Cell Surface Receptors for Kidney Basement MembranesAmerican Journal of Kidney Diseases.  12:78-83. 1988
    1988 Clinically significant valvular heart disease in systemic lupus erythematosusAmerican Journal of Medicine.  85:645-650. 1988
    1983 Leukemoid Blood Reaction to TetracyclineSouthern Medical Journal.  76:1195-1196. 1983


    Year Title Altmetric
    2018 Management of autoimmune and inflammatory disorders in the setting of infection or immunodeficiency.  427-443. 2018

    Research Overview

  • Lupus
    Immunodeficiency associated autoimmunity
    Macrophage activation syndrome
  • Education And Training

  • University of North Carolina Hospital, Internship
  • Doctor of Medicine, Vanderbilt University 1980
  • Bachelor's Degree in General Studies, Duke University 1976
  • University of North Carolina Hospital, Residency 1983
  • UAB Hospital, Postdoctoral Fellowship 1989
  • Full Name

  • W. Winn Chatham